Connecticut Expands Its Psychedelic Therapy Pilot Program Ahead of Possible Federal Approval
Gov. Ned Lamont has signed Senate Bill 191, a measure that expands the state’s existing psychedelic therapy pilot program.
Read More
3 Best Ketamine Clinics in Bend, Oregon (2026) — Verified & Reviewed
Pricing benchmarks below reflect our 2026 national dataset; Bend-specific clinic data appears in the rankings further down this article. HealingMaps Original Research n=verified pricing across 1,800 clinics · 23,496 inquiries · Oct 2022–Mar 2026 National pricing context for the Bend market: $300–500 IV, $590 Spravato, $150/month at-home maintenance. Bend is Central Oregon’s hub for interventional […]
Read More
FDA Faces a Core Problem in Psychedelic Trials: Everyone Knows Who Got the Drug
In many studies, participants can tell when they received the active drug. That makes these trials functionally open label.
Read More
Ketamine’s Depression Effects May Be More Complicated Than We Thought
A new commentary in The American Journal of Psychiatry argues that ketamine’s antidepressant effects may involve a wider set of brain systems.
Read More
Navy Veteran Creates App to Track Mental Health Changes From Psychedelics
The app, called INVI Mindhealth, was created by former Navy SEAL Jonathan Wilson after he sought psychedelic treatment outside the US.
Read More
New Psilocybin Study Finds Rapid Depression Relief After One Dose
There's a new Swedish clinical trial that adds to the growing case for psilocybin as a fast acting depression treatment.
Read More
Insurance Trade Publication Urges Insurers to Prepare for Psychedelic Medicine
Insurance Business, a trade publication for the insurance sector, is now telling insurers to pay closer attention to psychedelic medicine. In a recent column, neuropsychopharmacologist Dr. Rayyan Zafar argued that psychedelic therapies are moving from fringe science into clinical, commercial, and regulatory reality. His larger point was not subtle. Insurers should not wait for the […]
Read More
Michigan Rep. Jack Bergman Says Psychedelic Treatment Research Has Reached a New Moment
Rep. Jack Bergman, a Michigan Republican and one of Congress’s leading voices on psychedelics, says the window for action has opened wider.
Read More
Psychedelic Drug Market Could Reach $14.9 Billion by 2035, Report Says
The forecast reflects a shift in mental health, where ketamine, psilocybin, MDMA, and other compounds are moving from fringe to mainstream.
Read More
New Review Finds Ketamine May Ease Depression Within Hours and Reduce Suicidal Ideation
A new JAMA Psychiatry review shows intravenous ketamine can reduce depressive symptoms and suicidal thinking quickly
Read More